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Andrea A. Zachary* and Mary S. Leffell*
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
HLA matching provides numerous benefits in organ transplantation including better 
graft function, fewer rejection episodes, longer graft survival, and the possibility of 
reduced immunosuppression. Mismatches are attended by more frequent rejection 
episodes that require increased immunosuppression that, in turn, can increase the risk 
of infection and malignancy. HLA mismatches also incur the risk of sensitization, which 
can reduce the opportunity and increase waiting time for a subsequent transplant. 
However, other factors such as donor age, donor type, and immunosuppression 
protocol, can affect the benefit derived from matching. Furthermore, finding a well-
matched donor may not be possible for all patients and usually prolongs waiting time. 
Strategies to optimize transplantation for patients without a well-matched donor should 
take into account the immunologic barrier represented by different mismatches: what 
are the least immunogenic mismatches considering the patient’s HLA phenotype; 
should repeated mismatches be avoided; is the patient sensitized to HLA and, if so, 
what are the strengths of the patient’s antibodies? This information can then be used to 
define the HLA type of an immunologically optimal donor and the probability of such a 
donor occurring. A probability that is considered to be too low may require expanding 
the donor population through paired donation or modifying what is acceptable, which 
may require employing treatment to overcome immunologic barriers such as increased 
immunosuppression or desensitization. Thus, transplantation must strike a balance 
between the risk associated with waiting for the optimal donor and the risk associated 
with a less than optimal donor.
Keywords: HLA matches, HLA mismatches, immunogenicity, match probability, sensitization, repeated 
mismatches, donor-specific antibody
iNTRODUCTiON
There is overwhelming evidence of the benefits of HLA matching in organ transplantation including 
better graft function, longer graft and patient survival, and reduced risk of sensitization. However, 
when a well-matched related donor is not available, the wait for a well-matched unrelated donor 
can be prolonged, which can reduce quality of life, impede physical and cognitive development 
in the young, and increase the risk of death. Furthermore, in countries where there is substantial 
Abbreviations: CPRA, calculated panel reactive antibody; FCXM, flow cytometric crossmatch; PRA, panel reactive antibody; 
SPI, solid phase immunoassay; USRDS, United States Renal Data System.
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ethnic diversity, allocation of deceased donor organs by HLA 
match can result in a disparity, among ethnic groups, in access 
to transplantation. The effects of HLA matching are confounded 
by many factors that can affect outcome such as sensitization, 
immunosuppression, recipient ethnicity and age, and donor type 
and quality. Thus, transplantation is a balancing act between 
capturing the benefits of a well-matched transplant and dimin-
ishing the problems associated with achieving that transplant. 
Strategies must consider both the benefits and disadvantages 
of matching, the detrimental effects of mismatching, and what 
can be done to minimize negative effects of both matching 
and mismatching.
Here, we will review the impact of HLA matching/mismatch-
ing on graft outcomes, other factors that impact the effect of HLA, 
other consequences of mismatches, and the factors that should 
be evaluated – HLA antigens, epitopes, and amino acids. We will 
examine the effect of HLA mismatches on the current transplant 
and on future transplants as well as HLA matching strategies for 
the non-sensitized and sensitized patients.
eFFeCT OF HLA MATCHiNG/
MiSMATCHiNG ON OUTCOMeS
Assessment of the effects of mismatching has been confounded by 
variability over time of the ability to determine HLA phenotype 
accurately; by considering only matched but not mismatched 
antigens; by evaluating the effect of only some HLA loci; and by 
the diminished sensitivity and specificity of cell-based tests for 
HLA antibody. Although numerous early studies reported that 
increased numbers of matched antigens or decreased numbers of 
mismatched antigens led to improved graft and patient survival, 
improved graft function, and fewer rejection episodes, later 
reports suggested that ongoing improvements in immunosup-
pression therapies either diminished or eliminated any benefit of 
matching. However, large studies and more recent reports have 
reaffirmed the benefits to be derived from matching. Data from 
the Collaborative Transplant Study showed that with or without 
cyclosporine use, the renal transplant success rate was 20% higher 
when there was no mismatch of HLA-B and -DR than when there 
was a mismatch (1). Similarly, data from the United Network for 
Organ Sharing showed that long-term graft survival of deceased 
donor renal transplants with no HLA-A, -B, and -DR mismatch 
was nearly 20% better than for fully mismatched grafts with a 
stepwise reduction in survival with each increased degree of 
mismatch (2). Similar results were observed in a study of more 
than 150,000 renal transplants in which 10-year graft survival of 
first deceased donor kidney transplants was 17% higher among 
the zero HLA-A, -B, and -DR-mismatched patients than among 
those fully mismatched with an even greater benefit derived in 
sensitized patients (PRA >50%) (3). When graft survival was 
examined for deceased donor renal transplants occurring in dif-
ferent eras, it was seen that 5-year graft survival was 11% higher 
among transplants occurring between 1995 and 2004 compared 
to those occurring in the 10  years prior (73 vs. 62%) and that 
the strength of the association with HLA mismatch decreased in 
the second decade, but was still present. Furthermore, an asso-
ciation between extent of mismatch and treatment for rejection 
was present in both decades (4). In contrast, Su et  al. found a 
diminishing benefit of HLA matching in deceased donor renal 
transplants over the period 1995–1998 (5). A single center study 
showed a dramatic benefit of HLA matching among highly 
sensitized patients receiving deceased donor kidney transplants 
(6). One hundred and forty-two patients with CPRA >80%, nega-
tive flow cytometric crossmatches (FCXM) with donor T and B 
lymphocytes, and no detectable donor-specific antibody tested by 
ELISA, were grouped according to mismatch. For patients with 
0–2, 3–4, or 5–6 HLA-A, -B, and -DR mismatches, the incidence 
of rejection was 4.4, 11.4, and 31.3% and 5-year graft survival was 
100, 81, and 74%, respectively. This study found a strong effect of 
HLA-A, but not -B or -DR mismatch on graft loss. Others have 
found that mismatches for class I and class II had independent 
effects on patient survival where 0-DR/2-4AB and 0-1AB/1-2DR 
mismatches had 10-year patient survival of 86 and 89%, respec-
tively, compared to only 74% for 1-4 AB/1-2DR mismatches. The 
best survival of 92% was with mismatches limited to 1 A or B 
antigen. Freedom of graft failure due to immunologic causes was 
96.5% for mismatches limited to 1 A or B antigen and no DR 
mismatch and was 89–91% for all other mismatch groups (7).
Although there had been reports of the role of HLA-A and/
or -B mismatch, it eventually became apparent that of the HLA 
antigens tested routinely, HLA-DR matching contributed the 
most to graft survival and function. This is of particular impor-
tance since there are fewer antigens encoded by the DRB1 locus 
than by either the A or B loci making it easier to find zero DR 
mismatches compared to zero A or B mismatches, particularly 
when dealing with a very HLA heterogeneous population as in 
the United States. Connolly et  al. (8) showed that among 516 
primary deceased donor kidney recipients, zero DR-mismatched 
transplants had significantly better survival than those with 
even a single DR mismatch at both 1 year (92.8 vs. 84.5%) and 
5 years (88.3 vs.73.9%) (P < 0.0001). The effect was independent 
of HLA-A or -B match but diminished if cold ischemia time was 
more than 26  h. Al-Otaibi et  al. (9) found that pediatric renal 
patients who received fully DR-matched grafts had significantly 
better graft survival than did those receiving grafts with one or 
two DR mismatches. However, in this study, there were more liv-
ing donors in the well-matched group, which most likely contrib-
uted to the outcomes. It is not clear why matching for DR would 
be more important than matching for HLA-A or -B. Perhaps, 
DR antigens are more immunogenic than are A or B antigens. 
Perhaps, there is a gene dose effect. There is strong linkage 
disequilibrium within the HLA complex such that mismatching 
for DR may also increase the likelihood of mismatching for DQ 
antigens that have not been included in many evaluations of asso-
ciations between match and outcome. Additionally, mismatching 
for DRB1 antigens may also include a mismatch for the antigens 
encoded by the linked DRB3, 4, and 5 loci that encode DR52, 53, 
and 51, respectively. Figure 1 shows that most DR haplotypes are 
fixed such that DR15 or 16 also have the DRB5 gene that encodes 
DR51. Haplotypes with DR11, 12, 13, 14, 17, or 18 bear the DRB3 
gene that encodes DR52 and haplotypes with DR4, 7, or 9 have 
the DRB4 gene that encodes DR53. (Note that some very rare 
DR1 haplotypes also have the DRB5 gene. Also, an exception 
occurs on haplotypes bearing DR7 and DQ9. These haplotypes 
TABLe 1 | effect of gene dose of mismatched antigen.
Mismatched antigen Mean graft survival (years)
Heterozygous Homozygous
1 HLA-B 20.1 6.7
1 HLA-DR 16.9 14.7
1 each HLA-A, -B, -DR 15.0 13.0
10-year graft survival (%)
1 HLA-B 85 0
1 HLA-DR 87 67
1 each HLA-A, -B, and -DR 84 70
Homozygosity with two copies of a mismatched antigen, compared to heterozygosity 
with a single copy, was associated with reduced mean graft survival and 10-year graft 
survival. Adapted from Kim et al. (12).
FiGURe 1 | Gene organization of HLA-DR haplotypes. DR haplotypes have varying numbers of genes, some of which encode a polypeptide chain (filled boxes) 
and others are pseudogenes that have no detectable product (open boxes). DR molecules are comprised of two polypeptide chains, an α chain and a β chain. All 
DR haplotypes have a DRA gene that encodes the relatively invariant α chain and a DRB1 gene that encodes the β chain of the DR1-DR18 antigens. Some 
haplotypes carry an additional gene, DRB3, 4, or 5, that encodes the β chain of the DR52, 53, or 51 molecules, respectively. DR haplotypes can be grouped into 
families defined by the number of DRB genes present as shown in the diagram.
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have a null allele at the DRB4 locus and do not express DR53.) So 
that a patient with a DR1, DR4 phenotype, who is mismatched 
with a DR11, 12, 13, 14, 17, or 18, is also mismatched for DR52. 
To complicate matters further, DR52 antigens share an epitope 
with DR11, 12, 13, 14, 17, and 18 (10) and with DR8 (11) so that 
in addition to two mismatched antigens, there is a double dose of 
the shared epitope. Indirect evidence to support the possibility of 
a gene dose effect was reported by Kim et al. (12) who assessed 
graft survival in patients mismatched for one or more antigens 
present in either the heterozygous state (one copy of the antigen) 
or homozygous state (two copies of the mismatched antigen) with 
the latter being scored as a single mismatch in most studies. They 
found that zygosity affected both mean and 10-year survival with 
worse outcomes occurring with two doses of the mismatched 
gene (Table 1). In the past decade, there have been numerous, 
additional reports correlating improved outcomes with reduced 
mismatches of HLA-A, -B, and/or -DR antigens (13–19), and 
there has been little or no evidence to the contrary.
Nearly, all studies have examined outcomes vis-a-vis matching 
or mismatching of HLA-A, -B, and -DRB1-encoded antigens. 
However, at the time of this writing, there are limited data on 
matching at other HLA loci (HLA-C, -DRB3, -DRB4, -DRB5, 
-DQA, -DQB, -DPA, and -DPB). Frohn et  al. investigated the 
impact of HLA-C mismatches on rejection in 104 renal trans-
plants (20). They controlled for HLA-B mismatch to eliminate 
linkage disequilibrium as a confounding factor. They found that 
patients with one or two mismatches for an HLA-C antigen had a 
significantly higher incidence of rejection compared to those with 
no HLA-C mismatch (54 and 100 vs. 0%) but only when there 
was also one HLA-B mismatch. Patients with one HLA-B and 
two HLA-C mismatches also had decreased graft survival that 
approached statistical significance (P = 0.055). In an early study 
of data from the Southeastern Organ Procurement Foundation 
on 12,050 first deceased donor transplants, no effect of matching 
for HLA-DQ was found when other factors affecting outcome 
were taken into account (21). In contrast, in a recent study, Lim 
et al. found DQ mismatching to incur a significantly increased 
risk of rejection that was further increased in the presence of DR 
mismatches (22). Rosenberg et al. (23) found that DP mismatches 
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in patients matched for DR and DQ did not impact graft survival 
or function. Similarly, data from the Collaborative Transplant 
Study found no deleterious effect of DP mismatches in first 
deceased donor transplants but did find significantly reduced 
graft survival in regraft patients (24). The widespread adoption 
of DNA-based typing methods has facilitated typing for HLA-DQ 
and -DP. However, unlike other HLA molecules that have one 
polypeptide chain that is invariant or has limited variability, both 
polypeptide chains, the α chain encoded by DQA and DPA and 
the β chain encoded by DQB and DPB, are polymorphic. Both 
chains may have immunogenic epitopes and there are epitopes 
comprised of particular combinations of α and β chains (25, 26). 
Consequentially, studies that consider matching only for DQB 
and DPB may incorrectly identify a mismatch as a match between 
a donor and recipient.
The benefits of matching have been seen in all or nearly all 
types of transplants defined by organ type including heart 
(27–32), lung (33–36), liver (37–40), and pancreas (41, 42). It 
should be noted, however, that there are numerous reports of a 
lack of an effect of HLA matching on outcomes in liver transplan-
tation. The production of large amounts of soluble HLA class I 
molecules and the dual vasculature of the liver may reduce the 
susceptibility of this organ to immune attack. Regarding pancreas 
transplantation, most studies of matching have been of simulta-
neous kidney–pancreas transplants. The two citations here are of 
pancreas only transplants.
Other effects of HLA Mismatches
In separate reports from the Collaborative Transplant Study, it 
was shown that HLA mismatches were associated with death with 
functioning graft and with posttransplant lymphoproliferative 
disease. Increasing numbers of HLA mismatch in renal trans-
plantation were associated with an increased need for antirejec-
tion therapy that might account for an increased incidence of 
death with functioning graft due to infection and cardiovascular 
disease (43). It was also shown that among 9,209 pediatric kidney 
transplants, HLA-A, -B, and -DR mismatches were a risk factor 
for 5-year graft survival, but two DR mismatches appeared to 
incur an increased risk for non-Hodgkins lymphoma (44). There 
is a differential cost associated with different degrees of HLA 
match. Schnitzler et al. looked at Medicare payment information 
in the United States Renal Data System (USRDS) according to the 
degree of HLA mismatch. At three years, Medicare payments for 
zero, 1–3, 4–5, and 6 antigen mismatches were $60,400, $64,000, 
$71,000, and $81,000, respectively (45). Increased sensitization 
associated with HLA mismatches and HLA matching strategies 
are topics requiring more extensive discussion and will be dis-
cussed below.
OTHeR FACTORS ReLATeD TO 
MATCHiNG AND OUTCOMeS
Regrafts
Coupel et al. (46) reported on 233 second renal transplants for 
which repeated mismatches were permitted when no antibody 
to the mismatch was present. They found that DR mismatch 
was a major predictor of graft loss with DR mismatched patients 
having 5- and 10-year graft survival rates of 73 and 54%, respec-
tively, compared to 82 and 69% for zero DR mismatches. Others 
have investigated if there was a risk associated with repeated 
mismatches in regrafts. Cabacungan (47) found no effect 
of a repeated class I (HLA-A, -B) mismatch, but saw a 5–8% 
decrease in 1-year graft survival when there was a repeated DR 
mismatch. This is in contrast to a report of transplants occur-
ring in Southeastern Organ Procurement Foundation member 
centers, which found a lack of risk associated with repeated 
mismatch occurring in 158 of 753 regrafts (48). Doxiadis et al. 
(49) found that repeated DR mismatches, but not repeated A 
or B mismatches, significantly reduced 1-, 3-, and 5-year graft 
survival and that the effect was magnified when the survival 
of the first graft was less than 6  months. Tinckam et  al. (50) 
looked at the effect of a repeated mismatch present in 3,868 of 
13,789 regrafts listed in the USRDS. They found that repeated 
class I or class II mismatches were a risk for graft loss in patients 
who underwent transplant nephrectomy of the first transplant 
prior to receiving the second transplant and that the effect was 
stronger with class II mismatches. Repeated class II mismatches 
were also a risk factor in sensitized patients. They postulated that 
sensitization may be a marker for a more aggressive responder 
type or an indication of undetected low-level antibody to the 
repeated mismatch. Risk of graft loss was limited to those two 
subgroups of patients, sensitized patients, and patients who had 
undergone nephrectomy of the previous transplant. This report 
is extremely important because avoiding repeated mismatches 
unnecessarily reduces a patient’s chance for transplantation and 
increases waiting time while increasing immunosuppression in 
the face of a repeated mismatch may be unnecessary and incur 
an increase in the attendant side effects. Additional studies could 
determine further the level of risk associated with repeated mis-
matches, particularly among patients who are neither sensitized 
nor have had a nephrectomy of a previous transplant.
Recipient Race
Historically, Black recipients were considered to have poorer 
survival of renal grafts compared to White recipients. However, 
there are limited data on potentially combined effects of HLA 
matching and recipient race. Butkus et al. (51) showed that the 
effect of HLA mismatching in deceased donor transplantation 
was comparable in Blacks and Whites but that Blacks had, on 
average, more antigen mismatches. They found that the poorer 
graft survival among Black patients was attributable to socio-
economic factors, such as the type of insurance coverage and 
non-compliance. Smith and Butterly (52) saw a disparity between 
Black and White recipients of living donor transplants at all levels 
of match but that the disparity was diminishing over time from 
1985 to 2000.
Donor Factors
Donor factors, such as age and type, may exacerbate or reduce 
the effect of HLA mismatches. Using USRDS data for pediatric 
renal transplants occurring during 1994–2004, Foster et al. (53) 
examined the effect of HLA mismatch with consideration of 
donor age and further categorized transplants by donor type 
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(deceased or living). Donors were grouped by age in 5-year 
increments up to the age of 50 with donors older than 50 com-
prising the last group. They found that, among deceased donor 
transplants, there was a significant difference in graft survival 
between the best- and worst-matched transplants with each 
increasing number of mismatches increasing the risk of graft 
failure by 4% with donors 35  years old or older. Among the 
deceased donor transplants, young donor age offset the impact 
of poorer matches while better matches ameliorated the negative 
impact of older donor age. Among living donor transplants, they 
found that HLA mismatch, but not donor age, was relevant to 
graft survival and that 5-year graft survival was better among 
poorly matched living donor transplants than among well-
matched transplants with deceased donors of any age. Similarly, 
Terasaki et al. (54) reported that 10-year graft survival was better 
with five to six mismatched antigens when the donor was young 
than with zero mismatches and donor age greater than 55 years. 
A study of risk factors among 1,632 living donor renal trans-
plants found that risk factors for patient survival were donor 
>65 years old and five to six antigen mismatch, while risk factors 
for graft survival were donor >65 years old and a mismatch of 
three antigens or more (55).
immunosuppression
It was believed that the development and use of cyclosporine and 
lymphocyte depleting agents would diminish or negate the effect 
of HLA on outcomes, but the impact was limited. However, 
there is currently a wide array of therapeutic agents used for 
induction, maintenance immunosuppression, and/or treatment 
of rejection, and these may have a more substantial impact on 
the effect of HLA mismatches. In 2001, Meier-Kriesche et  al. 
(56) compared the effects of mycophenolate mofetil (MMF) and 
azathioprine on matching in 8,459 and 11,216 first renal trans-
plants. They found that there was less graft loss with MMF than 
with azathioprine, but that there was still a significantly lower 
rate of graft loss among zero mismatched (3.5%) compared to 
six antigen-mismatched transplants (11.3%) and that there was 
an incremental increase in risk of graft loss with each increase 
in the number of mismatched antigens. Also, they showed that 
mismatches of one or two antigens with azathioprine treatment 
had better graft survival than six antigen mismatches treated 
with MMF. As noted above, Opelz and Döhler (4) examined 
the impact of HLA in two different decades (1985–1994 and 
1995–2004) and saw that the impact was diminished in the 
second decade, but was still strong. Martins et al. (57) also saw 
a diminished impact of HLA matching with triple therapy of 
MMF, antithymocyte globulin, and tacrolimus. However, from 
the more current references cited above, it is apparent that HLA 
matching still provides the benefits of longer graft survival and 
better graft function.
Opportunity for Transplantation and 
Allocation of Deceased Donor Organs
Although transplanting well-matched organs is highly desirable, 
the high degree of polymorphism in the HLA system results 
in a low likelihood of finding a well-matched, unrelated donor 
even when only HLA-A, -B, and -DR are considered (58). This 
is particularly true where there is great HLA heterogeneity, 
as in the United States. This is born out by the distribution 
of zero-mismatched deceased donor renal transplants in the 
United States during the period 1998–2001. The percentage 
of each group receiving a zero A, B, and DR mismatch was 
21.4% of Whites, 7% of Blacks, 14.3% of Hispanics, and 6.6% 
of Asians (59). Considering only partial matching such as for 
HLA-DR, Vu et al. (60) determined that the average probability 
of finding a zero DR mismatch among local donors was 5% 
and this value was reduced to 2% when ABO compatibility was 
considered. Of course, the probability of a well-matched donor 
among first degree relatives is appreciably higher; however, this 
opportunity is not available to the vast majority of patients who 
need a kidney transplant. The desire for a well-matched donor 
should be balanced with a reasonable probability of finding 
such a donor. Algorithms for calculating the frequency of a 
donor who is a zero mismatch at a single locus or at any two 
or more loci are shown below (61). It is necessary to have 
allele and haplotype frequencies to perform the calculations, 
which can be found at various web sites. For frequencies for 
deceased donors where the donor population is comprised of 
different ethnic groups, the calculations should be done for 
each group that is a substantial proportion of the population. 
The values for each group should be weighted according to 
their proportion in the donor population and the weighted 
values should be summed to derive the probability of a donor 
in the total population.
Frequency of a Donor Who Is a Zero Mismatch  
at a Single Locus
This is a relatively easy calculation but must use allele, not antigen, 
frequencies. If the patient is homozygous for an antigen then, if i 
represents the frequency of the patient’s allele for the homozygous 
antigen, the frequency of a donor who is a zero mismatch at that 
locus is i2.
If the patient is heterozygous for an antigen and the frequen-
cies of the patient’s alleles at that locus are given by i and j, then 
the frequency of a zero mismatch at one locus is
 
P i ij j
i j
zero single locus mm   ( ) = + +
= +
2 2
2
2
( ) .  
Note that there may be several alleles that encode a serologi-
cally defined antigen. Then the allele frequency for that antigen 
would be the sum of all the alleles that encode that antigen and to 
which the patient does not have antibody.
Frequency of Donor Who Is a Zero Mismatch  
at Two or More Loci
If the patient is homozygous at all loci under consideration, the 
probability of a zero mismatch is h2 where h is the frequency of the 
haplotype comprised of the loci under consideration.
If the patient is heterozygous at one or more loci then
 1. Determine all the haplotypes that can be included in the 
phenotype of the loci under consideration.
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 2. Assign a population frequency to each haplotype, repre-
sented by hn.
 3. The phenotype that has no mismatched antigens occurs when 
any one haplotype is in the homozygous state or with combi-
nations of any of two of the compatible haplotypes.
 4. This is given by h12 + h22 + h32 + …2h1h2 +  2h1h3 + … 
which reduces to (h1 + h2 + h3…)2
Example: frequency of a zero B, DR mismatch for a patient 
with the phenotype A1, A2; B8, B44; DR11, DR17. The haplotypes 
that have no mismatched antigens are B8/DR11, B8/DR17, B44/
DR11, and B44/DR17 that will have frequencies represented by 
h1, h2, h3, and h4, respectively. Then,
 
P h h h h h h
h h h h h
zero B DR mismatch  /( ) = + + + +
+ + +
1 2 3 4 2 1 2
2 1 3 2 1 4 2
2 2 2 2
2 3
2 2 4 2 3 4
1 2 3 4 2
h
h h h h
h h h h
+ +
= + + +( ) .  
The probability can then be used to determine the number of 
donors needed to achieve a certain probability of finding such a 
donor. This is determined by
 
P
n
y
donor with selected phenotype 
among  donors





 (= − −1 1 )n ,
 
where y is the probability a donor will have the selected phenotype 
and n is the number of donors,
 
1 1− = −( ) 



y P
n
n donor with selected phenotype 
among  donors 

( )− = −n y P log log 
donor with selected 
phenotype among 
1 1
n
n P
 donors
log 
donor with 
selected phenot














= −1 ype 
among  donorsn
y




















−( )log .1
 
For example, when the frequency of donors with the selected 
phenotype is 0.01, the number of donors, n, needed to achieve a 
95% probability of such a donor occurring is
 n = =log log 0 05 0 99 298. / . .  
When trying only to avoid unacceptable mismatches, the 
frequency of donors can be obtained from programs such as 
the UNOS CPRA calculator, which can be found at https://
optn.transplant.hrsa.gov/resources/allocation-calculators/cpra-
calculator/. The CPRA calculator determines the frequency of 
donors with unacceptable antigens using allele and haplotype 
frequencies in the United States donor population. The prob-
ability of a donor with no unacceptable antigens among n donors 
is given by
 
P
n
donor with no unacceptable 
antigens among  donors





 =1−CPRAn.
 
Following the derivation above,
 
n P= −














log
donor with no 
unacceptable antigens
l1 og CPRA.
 
So, for a patient with a CPRA of 0.95, the number of donors 
needed to have a 95% probability of finding such a donor is
 n = =log log  0 05 0 95 58. / . .  
HLA MiSMATCHeS AND SeNSiTiZATiON
Sensitization to HLA antigens can be provoked by transfusion, 
pregnancy, or transplantation. Of these, the rate of sensitization 
and the strength and duration of HLA antibodies is greatest 
for transplantation where more than 70% of transplantation 
patients become sensitized compared to approximately 40% of 
transfused patients and 11–19% of parous females (62). We previ-
ously examined the impact of varying degrees of mismatch for 
HLA-A, -B, -DRB1, -DRB3-5, and DQ, for a possible total of 10 
mismatches, among 534 renal transplant patients (63). We found 
that the rate and extent of sensitization was proportional to the 
degree of mismatch. There was a substantial increase in extent of 
sensitization, on average, for patients whose previous transplant 
involved mismatches of two or more antigens, regardless of the 
race, gender, or previous sensitization status of the patient. Wait 
list time is longer for sensitized patients than for non-sensitized 
patients and this incurs greater costs for dialysis and antibody 
testing. For patients on the waitlist in 1996 and 1997, we deter-
mined that the costs were $297,204, $480,803, and $1,036,078 
for patients with PRAs of 0–9, 10–79, and ≥80. These figures are 
likely to be much higher today with higher dialysis costs and more 
sensitive antibody tests, even when antibody testing frequency is 
reduced as a cost-saving measure. Thus, the more mismatches, 
the greater the risk of sensitization and the higher the cost of a 
subsequent transplant.
Willicombe et al. (64) looked at the de novo development of 
donor-specific antibody among 505 renal transplant recipients 
who had no pretransplant donor specific antibody when tested 
in multianalyte bead assays on the Luminex® platform. They 
found that 18.2% of patients made donor-specific antibody after 
transplantation. Of those, 30% were specific only for class I, 
45% only for class II, and 25% for both. Interestingly, half were 
specific only for DQ. The frequency of de novo donor-specific 
antibody among patients matched for 2DR vs. 2DQ antigens 
was 9.4 and 21%, respectively. In a smaller study, Tagliamacco 
et al. (65) found an even higher rate of posttransplant antibody 
following a first transplant in 82 non-sensitized pediatric renal 
transplant patients. In this study, 29% made donor-specific 
antibody de novo, 83% of which was specific for DQ. Similar 
to the findings of Lopes, Kosmoliaptsis et  al. (66) saw that 
67% of previously transplanted patients were sensitized. When 
examined by class of antigen mismatched, they found that 
HLA-A mismatches had a greater effect than either HLA-B 
or -C. For class II antigens, the effect was comparable for 
DR and DQ but greater than for class I with the resultant 
antibodies stronger than those for class I. Among patients who 
TABLe 2 | Frequency of response to mismatched HLA antigens.
Responsea HLA-mismatched antigen
A B DR DQB
Mean overall 53.2 42.4 52.6 59.0
Rangeb 30.8–76.2 15.0–66.1 40.0–73.0 47.4–90.0
Mean with no  
cross-reactive  
antigen in patient
60.2 52.0 61.0 71.3
Mean with  
cross-reactive  
antigen in patient
49.7 35.5 43.0 45.5
Frequencies of antibodies, defined by multiplexed bead assays, to mismatched HLA 
antigens were determined from 703 renal transplant patients who had no detectable 
donor-specific antibody before transplantation. The impact of patients having antigens 
in their phenotype that were cross-reactive with the mismatched antigen was also 
assessed. Adapted from Lucas et al. (80).
aPercentage of mismatched patients who made antibody.
bThe range of antibody response to different antigens within the locus.
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were sensitized prior to the initial transplant, the frequency of 
sensitization went from 13 to 34% for class I mismatches and 
from 5 to 22% for class II mismatches. Meier-Kriesch et  al. 
(67) looked at sensitization among nearly 16,000 patients who 
were relisted after the loss of a first graft. They found that 
increases in PRA and the odds of being newly sensitized were 
proportional to the number of previously mismatched HLA-A, 
-B, and -DR antigens. They saw a strong effect of mismatches 
of HLA-A and -B with two HLA-A mismatches producing a 
greater increase in PRA than did two HLA-B mismatches (23 
vs. 13%). Among patients with no HLA-A, -B mismatches, 
only 10% were newly sensitized upon being relisted but that 
increased to 50% for mismatched patients. Furthermore, they 
saw a greater increase in sensitization in Blacks compared to 
Whites (18.3 vs. 13.9%). This has implications for changes in 
United States deceased donor allocation policies as eliminat-
ing points for HLA-B matches has resulted in an increase 
in the percentage (48.1–52%) of deceased donor transplants 
going to Blacks with a concurrent increase in the frequency 
of two HLA-B antigens mismatched (46–72%) (68). In turn, 
this increased level of mismatch may drastically decrease the 
opportunity for a subsequent transplant. Evidence for this was 
presented in a report by Gralla et al. (69) who looked at data 
for nearly 12,000 pediatric renal transplant patients, 2,704 of 
whom experienced graft failure and were listed for another 
transplant. There were 1,847 who were retransplanted. Among 
patients who were retransplanted, the mean PRA had increased 
from 6 to 45% while among the 857 who did not receive another 
transplant, the mean PRA increased from 8 to 76%. The ability 
to obtain a subsequent transplant was inversely correlated with 
the number of previous mismatches. Eighty percent of patients 
whose first graft was mismatched for two or fewer antigens 
were retransplanted. The percentage dropped to 56% for more 
than three previous mismatches. In a similar study of 8,433 
pediatric patients, Foster et  al. (70) also saw a declension in 
the likelihood of a second transplant with increased numbers 
of mismatched antigens in a first graft.
The conundrum created by these data is that on the one 
hand, higher numbers of mismatches not only reduce graft life 
and function but also increase the risk of sensitization with a 
resultant decreased opportunity for a future transplant, which 
may have a greater impact on pediatric patients who will most 
likely need more than one transplant. On the other hand, the 
opportunity for finding a well-matched unrelated donor is 
small for the majority of patients and extended time waiting 
incurs increased morbidity and mortality. A compromise may 
be to select donors with mismatches that have a low probability 
of inducing a humoral response. It has been proposed that 
antibody response to a transplant correlates with epitope load 
presented by the donor HLA antigens or the number of amino 
acid differences in the membrane distal portions of donor and 
recipient HLA antigens and great interest has been generated 
in “epitope matching” (71–74). Epitope matching may be 
the answer to reduce the humoral response to mismatched 
grafts, however, greater elucidation of the antibody binding 
and immunogenic properties of proposed epitopes is needed 
before widespread clinical application is possible. The portion 
of the HLA molecule seen by the patient’s immune system 
is comprised of its two membrane distal domains. Epitopes 
may reside on the α helix of one or the other domain or 
may be formed by interaction of the two α helices. This was 
demonstrated clearly in exon shuffling experiments (75–77). The 
properties, such as electrostatic potential and hydrophobicity, 
of the amino acids that comprise an epitope affect the identity 
and immunogenicity of the epitope and must also be taken 
into consideration (78, 79). Improvements in HLA antibody 
identification have permitted serologic confirmation of several 
proposed epitopes. However, the sera of most patients contains 
a mixture of antibodies and it is often difficult to define epitope 
specificity precisely.
We investigated antibody specificity in 703 patients who 
developed antibody to donor HLA following the transplanta-
tion (80). This was not a study of the frequency of antibody 
development. The hypothesis was that if all HLA antigens are 
equally immunogenic, newly developed antibody should be 
specific for all the mismatched donor antigens. We found that 
the frequency of antibody response varied both among loci and 
among the different antigens at each locus (Table  2). We also 
found that the presence of an antigen in the patient’s phenotype 
that was cross-reactive with the mismatched donor antigen 
reduced the response to that antigen. The strength of the effect 
of a cross-reactive antigen in the patient’s phenotype varied 
among antigen pairs. An HLA-A1 in a patient diminished the 
response to an HLA-A3 mismatch by 44%, but an HLA-A11 in 
the patient diminished the response to HLA-A3 by only 19%. 
Interestingly, not only was there was a variability in the effect of 
cross-reactivity but also there was a directionality. For example, 
an HLA-A2 in the patient reduced the response to HLA-B57 
by 83%, but an HLA-B57 in the patient reduced the response 
to HLA-A2 by only 8%. Antibody response was not affected by 
the total number of mismatches, the number of mismatched DR 
antigens, nor the DR phenotype of the patient. These data could 
be used to identify the donor who would be the least likely to 
provoke a humoral response when several donors are available. 
Two groups of patients in particular may derive a greater benefit 
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from the consideration of the immunogenicity of donor antigens. 
Pediatric patients are likely to need more than one transplant in 
their lifetime and when well-matched donors are not available, 
it would be possible to use these data to limit the sensitization 
to the first transplant. Black patients have higher rates of sensi-
tization than do White patients. As of 2013, the percentage of 
different groups of patients on the United States wait list who are 
sensitized was 43, 35, and 33% for Blacks, Whites, and Hispanics, 
respectively (81). We also found a higher antibody response in 
Black vs. Whites in our study of immunogenicity, although the 
difference was not statistically significant. The racial disparity 
in deceased donor transplants in the United States has been 
attributed to the use of HLA matching in allocation schemes. 
However, this disparity is also due in part to a higher rate of 
sensitization among Black patients and to differences in the ABO 
distribution between the donor population and Black patients 
(82). Unfortunately, the utility of data on immunogenicity would 
be limited with deceased donor allocation schemes that are 
driven primarily by wait time.
HLA-MATCHiNG STRATeGieS 
FOR SeNSiTiZeD PATieNTS
Although it may be desirable to avoid all donor-specific antibod-
ies, this will prevent many patients from being transplanted. 
Several strategies have been developed to deal with sensitization. 
It is important to correctly identify all the HLA antibodies of a 
patient, assess the level of risk associated with those antibodies, 
determine the level of risk that is acceptable, and determine the 
likelihood of finding a suitable donor, that is a donor who meets 
the risk specifications.
Solid phase immunoassays (SPI) and, in particular, the multi-
analyte bead assay performed on the Luminex® platform provide 
outstanding sensitivity and specificity in HLA antibody detection 
and characterization. These assays have provided improved detec-
tion of antibodies specific for HLA-C, -DQ, -DP, and subtypes 
of serologic antigens defined by alleles within an antigen group. 
They are essential to the identification of epitopes and reveal low-
level sensitization not detected in cell-based assays. Utilization of 
SPIs is essential for safe transplantation of the sensitized patient, 
but accurate interpretation of results requires substantial experi-
ence and expertise. The high degree of sensitivity of these assays 
make them subject to interference from IgM, complement, and 
immune complexes (83), and the presence of distorted HLA 
molecules in the assay may lead to incorrect positive or nega-
tive results (84). SPIs are semiquantitative and should be used in 
conjunction with cell based assays (85) and the results correlated 
with crossmatch test results (86, 87). Tambur et  al. (88) have 
shown that titrating sera in the multianalyte bead assay provides 
a good indication of antibody strength and is very useful when 
cell-based assays cannot be performed either because of lack of 
donor cells or because of the presence of therapeutic cell deplet-
ing agents in the serum. One of the most difficult problems is 
determining a threshold for positivity – that is, knowing when an 
antibody is really present. Although manufacturers have greatly 
reduced lot-to-lot variability in sensitivity, the high sensitivity of 
these assays makes them susceptible to run-to-run and operator 
variability. Furthermore, there is bead-to-bead variability due to 
varying amounts of misformed molecules on different beads and 
greater antigen concentration on beads bearing HLA-C, -DQ, 
and -DP antigens. We have found that these problems are 
diminished somewhat with phenotype panels, but these panels 
are not sufficiently informative for broadly reacting sera. Using 
cutoffs for positivity that are too low may deprive some patients 
of safe transplants while cutoffs that are too high can represent 
an unrecognized risk.
There is a great deal of information about antibodies to HLA-
A, -B, and -DR and data about antibodies to other HLA antigens 
are increasingly available. SPIs have shown that antibodies to DQ 
are inordinately common following transplantation and their 
complexity is being increasingly appreciated (25, 26). As noted 
earlier, because both polypeptide chains of DQ molecules are 
polymorphic analysis of DQ reactive antibody must take into 
account both the DQA and DQB alleles. Antibodies to a unique 
combination of DQA and DQB are most readily recognized when 
a patient’s antibody reacts with a molecule bearing the patient’s 
own DQB but a different DQA and does not react with other DQ 
molecules bearing the same DQA or when the antibody reacts 
with only one molecule bearing a particular DQA and DQB but 
with no other molecules bearing either that DQA or DQB. Less 
is known about antibodies to HLA-C and DP. As early as 1986, 
hyperacute rejection of a renal allograft due to antibody to an 
HLA-C antigen was reported (89). More recently, Bachelet et al. 
(90) reported on loss of a renal graft they attributed to antibod-
ies to two donor Cw antigens. Although the flow cytometric 
crossmatch was positive, the mean fluorescence intensity (MFI) 
values were moderately low (6,931 and 8,920). The patient also 
had antibodies to donor DP antigens. Ling et al. (91) reported on 
eight patients with antibody to donor Cw antigens, one of which 
had a positive FCXM while the crossmatch tests of the other 
seven were negative. The patients were followed for 3–24 months 
during which there was no antibody-mediated rejection and no 
graft loss. While exceptional cases of acute rejection mediated by 
antibodies to HLA-C may occur, the inherently low expression of 
these antigens suggests that they may be more involved in chronic 
rejection (92).
There is complexity with DP antibodies that is the result of 
cross-reactivity between certain HLA-DR and certain HLA-DP 
antigens due to shared epitopes (93). Two sequence dimor-
phisms of DPB1 define the immunodominant serologic epitopes 
of HLA-DP. Callender et al. (94) showed that while 42% of 650 
patients on a renal waiting list had DP antibody, nearly 80% had 
antibody to the cross-reactive DR antigens. The strengths of most 
of the antibodies was low with only 3 of the 271 sera yielding a 
positive cytotoxicity crossmatch. Furthermore, 40% of patients 
with DP antibody had not been previously transplanted. These 
data suggest that much of DP reactivity may be cross-reactivity 
with DR which may account, to some extent, for the reduced graft 
function and survival associated with DR mismatching. What 
needs to be determined is the extent to which DP antibody alone 
is pathogenic. Jolly et  al. (95) reported two cases of antibody-
mediated rejection and graft failure due to antibody to donor 
DP. In neither case was there antibody to other donor antigens, 
nor did the donors have DR antigens cross-reactive with the DP 
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antibodies, suggesting that the graft failure was attributable to 
the DP antibodies. Redondo-Pachon et al. (96) observed higher 
rates of acute rejection and of delayed graft function when 
donor-specific antibodies included specificity for DP. Goral et al. 
(97) also reported antibody-mediated rejection in two patients 
who received kidneys from donors mismatched only for DP and 
who had flow cytometric positive crossmatches positive with 
donor B cells and negative with autologous B cells. Collectively, 
the data indicate that patients should be tested for antibodies 
to all expressed HLA loci – A, -B, -C, -DRB1, -DRB3-5, -DQA, 
-DQB, -DPB and most likely -DPA and that both donors and 
recipients should be typed for these loci.
Economic pressures have forced many transplant programs 
to reduce the amount of antibody testing performed especially 
for patients who are likely to wait a long time to transplantation. 
HLA antibodies can be transient, particularly those produced in 
response to transfusion or pregnancy. In the absence of a com-
plete screening history, it is possible that sensitization would not 
be recognized. The amount of risk associated with donor-specific 
antibody that is present historically but not currently has not 
been clearly resolved. Some reports indicate that renal trans-
plantation could be performed safely in the face of an historic 
positive, current negative crossmatch (98, 99). Lyne et al. (100) 
reported on 47 patients with positive historic, current negative 
crossmatches. However, only 18 of the 47 crossmatches remained 
positive after treatment of the serum with dithiothreitol, indicat-
ing that 29 of the positive crossmatch results were due to IgM 
antibody. Overall graft survival rates for patients with apparent 
IgG antibody were not significantly different from those with 
apparent IgM antibody. In contrast, Leavey et  al. (101) saw 
increased early acute rejection among patients with historic IgM 
(42%) or IgG T cell positive crossmatches (57%) compared to 
patients with historic B cell only positive crossmatches (32%) 
and the IgG-positive group also had reduced 1-year graft sur-
vival (71%) compared to the other two groups (95%). Using a 
method developed in our laboratory to enumerate HLA-specific 
B cells by staining B cells with HLA tetramers, we found that 
patients with an increased level of B cells specific for HLA-A2, 
-A24, or -B7 who did not have antibody to those specificities 
at the time of transplant made antibody specific for the HLA 
antigen for which they had increased level of B cells even if 
the transplant was not mismatched for those antigens. Patients 
without increased numbers of HLA-specific B cells did not make 
the antibody (102). One patient with elevated B cells specific for 
HLA-B7 was mismatched for the antigen. That patient made IgG 
antibody to B7 within 48 h of transplantation and experienced 
severe antibody-mediated rejection. The timing of the antibody 
appearance indicates an anamnestic response. Donor-specific 
antibody of the IgG class that appears within the first posttrans-
plant week reflects an anamnestic response that indicates a risk 
for patients with cryptic sensitization. A possible explanation 
for the apparently conflicting results cited above is that in some 
cases, the disappearance of antibody reflects a senescence of the 
immune response, while in others, it indicates an active sup-
pression. Another possibility is that certain immunosuppression 
agents abrogate an anamnestic response. We studied the effect 
of rituximab treatment on posttransplant antibody responses 
in 26 patients who had elevated HLA-specific B cells, but no 
antibody specific for the tested antigen at the time of transplant. 
Of patients treated with rituximab, 0 of 10 made antibody after 
transplantation while 13 of 16 who were not treated with rituxi-
mab did make antibody (103). These data suggest that a positive 
historic crossmatch or known previous sensitization represents 
a manageable risk that does not require avoiding those antigens 
to which a patient was previously sensitized.
Strategies for transplanting sensitized patients include avoid-
ing mismatches to which the patient currently has antibody, 
overcoming low-level donor-specific antibody with more intense 
immunosuppression, or eliminating or reducing donor-specific 
antibody to an acceptable level via desensitization applied prior to 
or at the time of transplantation. It is likely that no one approach is 
optimal for all patients and that transplanting sensitized patients 
in a timely and safe manner may require programs to utilize all 
three strategies, customized to the immune status and medical 
condition of each patient.
Finding donors to which a sensitized patient does not have 
antibodies has been greatly enhanced by kidney paired donation 
programs. These programs are directed toward patients who have 
a willing, but incompatible living donor. By transporting donor 
kidneys, recipients and donors can undergo surgery at their 
home institution. Another approach, the acceptable mismatch 
program, has significantly increased transplantation rates for 
patients awaiting a deceased donor transplant. This program 
was pioneered by Claas and colleagues in the Netherlands in the 
late 1980s (104). As initially implemented, the strategy was the 
determination of HLA-A and -B mismatches to which the patient 
had not formed alloantibodies. Successful implementation in 
Eurotransplant involved extensive antibody screening for HLA-A 
and -B specific antibodies coupled with sharing of sera among 
participating centers for crossmatching of all ABO-compatible 
donors. Allocation within Eurotransplant for the acceptable 
mismatch program affords highly sensitized patients the highest 
priority when a donor becomes available who is compatible with 
the patient’s antibody profile (105). Since its implementation in 
Eurotransplant, waiting time among highly sensitized patients 
has been significantly reduced while both short- and long-term 
graft survival comparable to non-sensitized patients has been 
achieved (105, 106). Use of current SPIs for definition of HLA-
specific antibodies, coupled with a molecularly based algorithm 
for determination of acceptable antigen mismatches has added 
to the potential application of acceptable mismatch programs 
(107, 108). In a cost-benefit analysis among patients on the 
deceased donor wait list in Australia, an acceptable mismatch 
allocation model was found to be an equitable approach to 
improve access for highly sensitized transplant candidates 
without compromising the benefits to other patients on the wait 
list (109). Acceptable mismatch programs have the advantages of 
being lower in cost and non-invasive compared to desensitiza-
tion protocols; however, a compatible donor may not be found 
for up to 40% of patients who may have rare HLA phenotypes 
and/or be very broadly sensitized (105, 110). The degree of HLA 
heterogeneity among the patient population compared to the 
donor pool is a factor in the United States with large numbers 
of Black transplant candidates, as the degree of HLA phenotype 
TABLe 3 | Number of donors needed for different CPRA levels.
CPRAa Number of donors required
95% probability of a donorb 99% probability of a donorb
0.9999 29,956 46,049
0.9990 2,994 4,602
0.9900 298 458
0.9500 58 90
0.9000 22 44
0.8500 18 28
0.8000 13 21
0.7500 10 16
The numbers (n) of donors required for 95 and 99% probability (P) of finding a 
compatible donor at different CPRA levels are shown. The numbers were derived by 
the following algorithm: n = log[1 − P(donor with no unacceptable antigens)]/log CPRA.
aThis is also 1- frequency of donors with no unacceptable antigens (see text).
bNumber of donors, rounded to nearest whole number, needed to have a 95 or 99% 
probability of an acceptable donor.
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heterogeneity is significantly higher among Blacks than among 
other ethnicities (58). Therefore, it has been recognized that 
for successful transplantation of highly sensitized patients, both 
acceptable mismatch programs and desensitization should be 
considered (110).
Low-level, donor-specific antibody is associated with an 
increased frequency of antibody-mediated rejection (111–113) 
and subclinical rejection (114) and reduced long-term graft 
survival (115, 116). However, despite efforts to avoid mismatches 
with a donor to whom a patient has antibodies, there remain 
patients for whom such a donor cannot be found. Dialysis reduces 
quality of life, is attended by numerous health issues particularly 
in young patients, and limits many activities enjoyed by healthy 
individuals. Ameliorating or delaying the effects of donor-
specific antibody can be achieved with various therapeutic agents 
and procedures such as lymphocyte and plasma cell-depleting 
agents, plasmapheresis, and intravenous immunoglobulin. 
It has been clearly demonstrated both in a single center (117) 
and a multicenter study (118) that desensitization provides a 
significant survival benefit over patients receiving a compatible 
deceased donor transplant or patients who remain on a wait list. 
Eliminating unacceptable antigens or antigens to avoid can be 
done by raising the threshold for what is unacceptable, without 
consideration of specificity or the breadth of sensitization. In an 
Australian kidney paired donation program with a registry of 53 
donor–recipient pairs and two altruistic donors, no matches were 
found using a cutoff of 2,000  MFI for acceptability. When the 
threshold was raised to 8,000, matches were found for 70% of the 
patients (119). The threshold for unacceptable antigens could be 
changed according to the correlation with crossmatch. That is, 
the threshold could be raised to just below what would yield a 
positive flow cytometric crossmatch. This may be more difficult 
to assess for donors to whom a patient has multiple antibodies 
as the collective strength of the antibodies is difficult to assess 
from SPIs. One may choose to eliminate unacceptable antigens 
by specificity or by source of sensitization. For example, one 
may choose to keep as unacceptable, antigens that were previous 
transplant mismatches and to which the patient has antibody at 
a low level. Ferrari et al. (87) have recommended raising unac-
ceptable thresholds only if desensitization treatment is available 
and if the antigens are not rare in the donor population. Using 
allele and haplotype frequencies or programs such as the CPRA 
calculator, one can determine the impact on the likelihood 
of finding a donor when unacceptable antigens are eliminated 
(shown above). Table 3 provides the number of unrelated donors 
needed for a 95 or 99% probability of finding a donor for different 
levels of CPRA.
One may eliminate unacceptable antigens by either class I or 
class II based on the differential expression of these antigens. 
Muczynski et  al. (120) reported that class II antigens were 
expressed constitutively in the endothelium of renal peritubular 
and glomerular capillaries. However, McDouall et al. (121) dem-
onstrated that class II was not expressed constitutively on large 
vessels. Several others have reported that cultured endothelial 
cells do not express class II constitutively (122–124). It is dif-
ficult to know if cultured cells are representative of the in vivo 
situation or if cells obtained via biopsy have been provoked to 
express class II. Our experience with desensitization indicated 
that patients with persistent DR or DQ antibody at a level 
below flow cytometric crossmatch had only a slightly increased 
frequency of antibody-mediated rejection compared to patients 
with no detectable donor-specific antibody and there was no 
increased rejection in patients with persistent antibody to DR51, 
52, or 53 (125). In fact, 10-year graft survival occurred with 
one patient who had persistent antibody to donor DR52 at the 
level of cytotoxicity. Antibody-mediated rejection occurred only 
when the patient was treated with thyroxine, an agent known to 
stimulate class II expression. Another patient had graft survival 
of at least 5 years with a DQ7 antibody that had spiked to a very 
high titer in the cytotoxicity assay following an anaphylactic 
reaction. These data and examples suggest that if HLA class II 
antigens are expressed constitutively on vascular endothelium, 
it is at low levels.
Thus, patients with levels of antibody that are naturally low or 
have been reduced by desensitization are able to be transplanted 
with reasonably good graft function and survival. However, these 
patients should be monitored frequently in the early posttrans-
plant period and periodically for the life of the graft for changes 
in antibody level. Pro-inflammatory events, such as infection, 
trauma (such as surgery), an allergic reaction, and blood transfu-
sion, can all stimulate non-specific activation of memory B cells 
leading to an increase in donor-specific antibody (126, 127). 
Finally, although not the topic of this review, it is worthwhile to 
mention that a very reasonable approach to transplanting the 
sensitized patient is with a donor who is well matched for HLA, 
but is ABO incompatible. This may be particularly beneficial to 
the pediatric transplant candidate (128).
SUMMARY
We have reviewed data here that are summarized as follows:
• All HLA mismatches are associated with some degree of risk 
of reduced graft function and survival and the risk is propor-
tional to the number of mismatched antigens.
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• Good HLA matches with unrelated donors are uncom-
mon, and the desire to achieve a good match should be 
balanced against the risk associated with prolonged time on 
dialysis.
• Repeated mismatches represent an increased risk only in 
sensitized patients or in patients who underwent nephrectomy 
of a previous graft.
• There are other deleterious effects of mismatching, one of the 
most serious being sensitization, which is most problematic 
for patients who will need another transplant.
• Balancing risk of sensitization and wait time may be achieved 
by favoring less immunogenic mismatches.
• Matching strategies for sensitized patients may be to avoid 
donor antigens to which a patient has antibody or to reduce 
antibody strength to an acceptable level and/or utilize more 
intense immunosuppression.
• Matching strategies should be customized to both the patient 
and to the transplant program’s resources.
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